查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000342

全球雙特異性抗體市場機會、劑量、專利、定價、銷售和臨床試驗展望（2031 年）

Global Bispecific Antibody Market Opportunity, Antibody Dosage, Patent, Price, Sales & Clinical Trials Outlook 2031
出版日期: | 出版商: KuicK Research | 英文 960 Pages | 商品交期: 最快1-2個工作天內

價格

全球雙特異性抗體市場機會、劑量、專利、定價、銷售和臨床試驗展望（2031年）報告的主要發現和亮點：

  • 已通過核准的雙特異性抗體數量：18
  • 全球和依區域分析年度和季銷售額
  • 全球雙特異性抗體市場機會：到2031年超過600億美元
  • 2025年全球雙特異性抗體市場規模：超過160億美元
  • 深入了解已通過核准的抗體劑量、專利、定價和銷售情況。
  • 對雙特異性抗體專有平台的深入了解：超過 30個平台
  • 對臨床試驗中超過 550 種雙特異性抗體的全面深入了解
  • 全球雙特異性抗體臨床試驗依公司、適應症及分期分類。

雙特異性抗體的必要性及本報告的意義

雙特異性抗體處於免疫療法和標靶治療創新發展的前沿，因為它們有望更有效地應對疾病的複雜性。隨著癌症治療中腫瘤異質性、訊號通路冗餘和治療抗藥性等挑戰不斷限制單藥療法的潛力，對雙特異性抗體療法的需求日益成長。

近年來，雙特異性抗體在醫藥市場取得了顯著成長，尤其是在癌症治療領域，它們利用免疫系統攻擊癌細胞展現出巨大的潛力。除了癌症之外，雙特異性抗體還在包括自體免疫疾病在內的廣泛領域進行評估。

全球雙特異性抗體市場估計2025年達到約169億美元，其中美國佔市場主導地位，佔總銷售額的60%以上。目前已有18種雙特異性抗體獲批上市，另有多種新藥候選藥物核准監管批准，在臨床進展穩步推進和行業持續投資的支持下，該市場正朝著商業性成熟邁進。因此，本報告對於希望在這個不斷成長的市場中取得成功的製藥公司、投資者和其他相關人員而言，都是一份極具價值的資訊來源。

報告中包含對臨床試驗的深入分析

臨床試驗在雙特異性抗體療法的研發中發揮了核心作用。尤其是在腫瘤學領域，許多針對不同適應症的雙特異性抗體進行臨床試驗，其作為骨髓惡性腫瘤和固體癌（例如非小細胞肺癌（NSCLC）和結直腸癌（CRC））治療藥物的潛力接受評估。

本報告對臨床試驗進行了系統性全面的分析，涵蓋了從初步人體試驗到確證性後期臨床試驗的各個階段。分析重點在於針對復發或難治性患者群體的研究，在這些研究中，雙特異性抗體已展現出令人鼓舞的療效。此外，也分析了研究設計、患者選擇標準、給藥策略和聯合治療。臨床策略的一個新趨勢是探索雙特異性抗體在腫瘤學以外的領域（例如自體免疫疾病和發炎性疾病）的應用，擴大其潛在應用範圍。雙特異性抗體進入後期研發階段和提交監管申請的進展表明，人們對這類藥物的信心日益增強。

專注於雙特異性抗體研發的主要企業

雙特異性抗體市場競爭異常激烈，既有老牌製藥公司，也有新興生技公司積極進軍該市場。JNJ、Amgen、Genmab 和Roche等領導企業憑藉著雄厚的財力、卓越的研發實力和穩固的腫瘤業務基礎，始終處於市場前沿。這些公司不斷拓展其雙特異性抗體產品線，涵蓋多個疾病領域，不僅鞏固了自身市場地位，也擴大了在該類藥物中的市場佔有率。同時，為了維持市場競爭力，它們也持續進行產品組合多元化。

同時，Invenra、Biosion 和 Alligator Bioscience 等新興生技公司也為該市場的發展做出了重要貢獻。這些公司不斷推出差異化的雙特異性抗體和新的潛在適應症，進一步活性化了市場競爭。

技術平台、合作夥伴關係和協議

技術創新是雙特異性抗體研發的核心。目前已開發出多種專有技術，用於最佳化雙特異性抗體的結合特異性、穩定性、生產流程和治療效果。這些技術包括雙特異性抗體末端連接酶（BiTE）、雙可變區域以及其他雙特異性抗體形式。

此外，合作關係和授權協議是加速研發進程和拓展臨床效用的關鍵要素。這些合作關係使各機構能夠充分利用彼此的專業知識，分擔研發風險，並加強全球商業化。Abbvie與RemeGen就RC148達成的協議就是一個絕佳的例子，它展現了策略合作如何推動下一代雙特異性抗體（尤其是聯合治療）的創新。

一份概述雙特異性抗體片段未來發展方向的報告。

在樂觀的預測下，雙特異性抗體市場預計未來將持續成長。這一市場成長預計將受到該領域臨床、技術和治療進展的推動。越來越多的後期臨床試驗表明，預計未來將有更多雙特異性抗體獲得監管部門的核准。這將進一步鞏固雙特異性抗體在現代醫學中的地位。

聯合治療有望在未來推動雙特異性抗體的廣泛應用。這一點在腫瘤治療領域尤其明顯，雙特異性抗體有望在與其他藥物的聯合治療中發揮非常重要的作用。此外，雙特異性抗體的進步預計在不久的將來帶來更好的臨床療效。

除了在腫瘤治療領域的應用外，雙特異性抗體也在自體免疫疾病和發炎性疾病領域進行研究。憑藉著積極的投資和策略合作，雙特異性抗體有望在推動各疾病領域下一代治療方法的研發中發揮關鍵作用。

目錄

第1章 調查方法

第2章 二價抗體概述

第3章 雙特異性抗體的聯合治療策略

  • 化療
  • 標靶治療
  • 免疫療法
  • 放射線治療

第4章 關於市售已通過核准特異性抗體的考量

  • 公司名稱、適應症、所在地和作用機制
  • 雙特異性抗體將被授予監管認定。

第5章 雙特異性抗體的獨特平台

第6章 雙特異性抗體市場的全球與區域展望

  • 年度和季銷售趨勢（2020-2025年）
  • 關於已通過核准的雙特異性抗體的償付和保險覆蓋範圍的政策
  • 全球雙特異性抗體市場預測（至2031年）

第7章 全球雙特異性抗體市場趨勢（依地區）

  • 美國
  • 歐洲
  • 中國
  • 英國
  • 日本
  • 韓國
  • 澳洲
  • 加拿大
  • 拉丁美洲

第8章 已通過核准的雙特異性抗體 - 臨床、專利、定價和行銷見解

  • Blincyto
  • Hemlibra
  • Rybrevant
  • Vabysmo
  • Lunsumio
  • Kaitani
  • Tecvayli
  • Columvi
  • Epkinly
  • Talvey
  • Elrexfio
  • Imdelltra
  • Ivonescimab
  • Ordspono
  • Ziihera
  • Bizengri
  • Korjuny
  • Lynozyfic

第9章 全球雙特異性抗體臨床試驗（依公司、適應症和階段）

  • 研究
  • 臨床前
  • 第一期
  • 第一/二期
  • 第二期
  • 第二期
  • 第二/三期
  • 第三期
  • 預註冊
  • 已註冊

第10章 市售雙特異性抗體的臨床研究結果（依公司、國家及適應症）

第11章 依適應症分類的雙特異性抗體全球調查及市場趨勢

  • 癌症
    • 骨髓惡性腫瘤
    • 固體癌
  • 自體免疫疾病與發炎性疾病
  • 血液疾病
  • 眼科疾病
  • 微生物疾病

第12章 競爭格局

  • AbbVie
  • ABL Bio
  • Abzyme Therapeutics
  • Affimed Therapeutics
  • Akeso Biopharma
  • Alligator Bioscience
  • Alphamab Oncology
  • Amgen
  • Antibody Therapeutics
  • APITBIO
  • Aptevo Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • BeOne Medicines
  • BioAtla
  • BioNTech
  • Biosion
  • BJ Bioscience
  • EpimAb Biotherapeutics
  • FutureGen Biopharmaceutical
  • Genentech
  • Genmab
  • Gensun Biopharma
  • Harbour BioMed
  • ImmuneOnco Biopharma
  • Innovent Biologics
  • Invenra
  • Jazz Pharmaceuticals
  • Johnson & Johnson
  • Kenjockety Biotechnology
  • LaNova Medicines Limited
  • Light Chain Bioscience
  • Lindis Biotech
  • Linton Pharm
  • Lyvgen Biopharma
  • MacroGenics
  • Merus
  • NovaBridge Biosciences
  • NovaRock Biotherapeutics
  • Novo Nordisk
  • Pfizer
  • Phanes Therapeutics
  • Prestige BioPharma
  • Regeneron Pharmaceuticals
  • Revitope
  • Roche
  • Summit Therapeutics
  • Virtuoso Therapeutics
  • Xencor
  • Zymeworks

Global Bispecific Antibody Market Opportunity, Antibody Dosage, Patent, Price, Sales & Clinical Trials Outlook 2031 Report Findings & Highlights:

  • Number Of Approved Bispecific Antibodies: 18
  • Global, Regional Annual & Quarterly Sales Insight
  • Global Bispecific Antibodies Market Opportunity: > USD 60 Billion By 2031
  • Global Bispecific Antibodies Market In 2025: > USD 16 Billion
  • Approved Antibodies Dosage, Patent, Pricing & Sales Insight
  • Insight On Bispecific Antibodies Proprietary Platforms: >30 Platforms
  • Comprehensive Insight On More than 550 Bispecific Antibodies In Clinical Trials
  • Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

Need For Bispecific Antibodies & Why This Report?

Bispecific antibodies have been at the forefront of revolutionizing the horizon of immunotherapy and targeted therapy due to their potential to address the complexities of disease more effectively. With the persistence of challenges in cancer therapy, tumor heterogeneity, pathway redundancy, and treatment resistance limiting the full potential of single-agent therapy, there is a growing need for bispecific antibody therapeutics.

In the recent years, bispecific antibodies have witnessed substantial growth in the pharmaceutical market, especially in cancer therapy, where they have been shown to have substantial potential in harnessing the immune system to fight cancer. Apart from cancer, bispecific antibodies have also been evaluated for autoimmune diseases and beyond.

The global bispecific antibody market was estimated to be around US$ 16.9 Billion in 2025, with the US dominating the market, representing more than 60% of the total sales. With 18 bispecific antibodies already approved and regulatory filings for additional candidates in progress, the market is transitioning toward commercial maturity, supported by strong clinical progress and continued industry investment. This report, thus, serves as a valuable asset to pharmaceutical companies, investors and other stakeholders seeking realization in this continuously expanding market

Clinical Trials Insight Included In Report

Clinical trials have been at the core of bispecific antibody therapeutics development. With a large pipeline of bispecific antibodies under clinical investigation for various indications, particularly in oncology, bispecific antibodies are being evaluated for their potential to treat hematological malignancies and solid tumors such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

The report undertakes a systematic and comprehensive analysis of clinical trials, covering first-in-human studies to confirmatory late-stage studies. Our analysis includes trial design, patient selection criteria, dose strategies, combination therapies, as well as special focus on studies conducted on relapsed or refractory patient populations, where bispecific antibodies have shown promising results. The emerging trends in clinical strategies are also exploring bispecific antibodies beyond oncology to other diseases such as autoimmune and inflammatory diseases, thereby expanding the potential application of bispecific antibodies. The progress of bispecific antibodies to late-stage development and regulatory submissions underscores the growing confidence in this class of drugs.

Major Companies Active In R&D Of Bispecific Antibodies

The bispecific antibody market has a competitive environment that is influenced by the active participation of both established pharmaceutical players as well as emerging biotechnology players. Established players such as JNJ, Amgen, Genmab and Roche are still at the forefront, backed by their financial capabilities, development expertise, as well as their existing oncology franchise. These players are continually expanding their bispecific antibody pipeline across various diseases, thereby not only strengthening their position but also expanding their presence in this class of drugs. However, they are also continuously diversifying their portfolios to remain competitive in the market.

On the other hand, emerging biotechnology players, such as Invenra, Biosion and Alligator Bioscience, are significantly contributing to the development of this market. These players are continuously entering this market with differentiated bispecific antibodies as well as novel potential applications, thereby adding to the competitive environment.

Technology Platforms, Collaborations & Agreements

Technological innovation is at the heart of bispecific antibody development. Various proprietary technologies have been developed to optimize bispecific antibody binding specificity, stability, manufacturability, and therapeutic efficacy. This includes formats such as BiTEs, dual variable domains, and other bispecific antibody formats.

Additionally, collaborations and licensing deals are an important factor in accelerating development pathways and expanding clinical utility. Such collaborations allow organizations to leverage mutual expertise and share developmental risks while improving global commercialization efforts. The Abbvie and RemeGen deal for RC148 is an excellent example of how strategic collaborations are driving innovation in next-generation bispecific antibodies, particularly in combination therapies.

Report Indicating Future Direction Of Bispecific Antibody Segment

The bispecific antibody market is expected to grow in the future with an optimistic outlook. The growth in this market is expected to be driven by clinical, technological, and therapeutic advances in the field. The increasing number of clinical trials in late stages suggests that more bispecific antibodies are expected to receive regulatory approval in the near future. This would further cement the position of bispecific antibodies in modern medicine.

Combination approach is expected to play an important role in driving bispecific antibodies in the future. This is particularly true in oncology indications where bispecific antibodies are expected to play an important part in combination therapies with other drugs. In addition to this, advances in bispecific antibodies are expected to drive better clinical outcomes in the near future.

In addition to oncology indications, bispecific antibodies are also being explored in autoimmune and inflammatory diseases. In conjunction with strong investment activity and strategic collaborations, bispecific antibodies are expected to play an important role in driving next-generation therapies in various disease indications.

Table of Contents

1. Reserch Methodology

2. Introduction To Bispecific Antibodies

3. Bispecific Antibody Combination Strategies

  • 3.1 Chemotherapy
  • 3.2 Targeted Therapy
  • 3.3 Immunotherapy
  • 3.4 Radiotherapy

4. Commercially Approved Bispecific Antibodies Insight

  • 4.1 Company, Indication, Location & MOA
  • 4.2 Bispecific Antibodies Granted Regulatory Designations

5. Bispecific Antibodies Proprietary Platforms

6. Global & Regional Bispecific Antibody Market Outlook

  • 6.1 Yearly & Quarterly Sales Insight (2020 To 2025)
  • 6.2 Approved Bispecific Antibodies Reimbursement & Coverage Policy
  • 7.10 Global Bispecific Antibody Market Forecast 2031

7. Global Bispecific Antibody Market Trends By Region

  • 7.1 US
  • 7.2 Europe
  • 7.3 China
  • 7.4 UK
  • 7.5 Japan
  • 7.6 South Korea
  • 7.7 Australia
  • 7.8 Canada
  • 7.9 Latin America

8. Approved Bispecific Antibodies - Clinical, Patent, Pricing & Sales Insight

  • 8.1 Blincyto
  • 8.2 Hemlibra
  • 8.3 Rybrevant
  • 8.4 Vabysmo
  • 8.5 Lunsumio
  • 8.6 Kaitani
  • 8.7 Tecvayli
  • 8.8 Columvi
  • 8.9 Epkinly
  • 8.10 Talvey
  • 8.11 Elrexfio
  • 8.12 Imdelltra
  • 8.13 Ivonescimab
  • 8.14 Ordspono
  • 8.15 Ziihera
  • 8.16 Bizengri
  • 8.17 Korjuny
  • 8.18 Lynozyfic

9. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Phase I
  • 9.4 Phase I/II
  • 9.5 Phase II
  • 9.6 Phase II
  • 9.7 Phase-II/III
  • 9.8 Phase III
  • 9.9 Preregistration
  • 9.10 Registered

10. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

11. Global Bispecific Antibodies Research & Market Trends By Indications

  • 11.1 Cancer
    • 11.1.1 Hematological Malignancies
    • 11.1.2 Solid Cancers
  • 11.2 Autoimmune & Inflammatory Diseases
  • 11.3 Blood Disorders
  • 11.4 Ocular Diseases
  • 11.5 Microbial Diseases

12. Competitive Landscape

  • 12.1 AbbVie
  • 12.2 ABL Bio
  • 12.3 Abzyme Therapeutics
  • 12.4 Affimed Therapeutics
  • 12.5 Akeso Biopharma
  • 12.6 Alligator Bioscience
  • 12.7 Alphamab Oncology
  • 12.8 Amgen
  • 12.9 Antibody Therapeutics
  • 12.10 APITBIO
  • 12.11 Aptevo Therapeutics
  • 12.12 Astellas Pharma
  • 12.13 AstraZeneca
  • 12.14 BeOne Medicines
  • 12.15 BioAtla
  • 12.16 BioNTech
  • 12.17 Biosion
  • 12.18 BJ Bioscience
  • 12.19 EpimAb Biotherapeutics
  • 12.20 FutureGen Biopharmaceutical
  • 12.21 Genentech
  • 12.22 Genmab
  • 12.23 Gensun Biopharma
  • 12.24 Harbour BioMed
  • 12.25 ImmuneOnco Biopharma
  • 12.26 Innovent Biologics
  • 12.27 Invenra
  • 12.28 Jazz Pharmaceuticals
  • 12.29 Johnson & Johnson
  • 12.30 Kenjockety Biotechnology
  • 12.31 LaNova Medicines Limited
  • 12.32 Light Chain Bioscience
  • 12.33 Lindis Biotech
  • 12.34 Linton Pharm
  • 12.35 Lyvgen Biopharma
  • 12.36 MacroGenics
  • 12.37 Merus
  • 12.38 NovaBridge Biosciences
  • 12.39 NovaRock Biotherapeutics
  • 12.40 Novo Nordisk
  • 12.41 Pfizer
  • 12.42 Phanes Therapeutics
  • 12.43 Prestige BioPharma
  • 12.44 Regeneron Pharmaceuticals
  • 12.45 Revitope
  • 12.46 Roche
  • 12.47 Summit Therapeutics
  • 12.48 Virtuoso Therapeutics
  • 12.49 Xencor
  • 12.50 Zymeworks

List of Figures

  • Figure 2-1: Bispecific Antibodies - Advantages
  • Figure 3-1: Antibody-Chemotherapy Combination - Advantages
  • Figure 3-2: Antibody-Chemotherapy Combination - Impending Challenges
  • Figure 4-1: Blincyto - Mechanism Of Action
  • Figure 4-2: Hemlibra - Mechanism Of Action
  • Figure 4-3: Rybrevant - Mechanism Of Action
  • Figure 4-4: Tecvayli - Mechanism Of Action
  • Figure 4-5: Columvi - Mechanism Of Action
  • Figure 4-6: Epkinly - Mechanism Of Action
  • Figure 4-7: Talvey - Mechanism Of Action
  • Figure 4-8: Elrexfio - Mechanism Of Action
  • Figure 4-9: Imdelltra - Mechanism Of Action
  • Figure 4-10: Ivonescimab - Mechanism Of Action
  • Figure 4-11: Ziihera - Mechanism Of Action
  • Figure 4-12: Lynozyfic - Mechanism Of Action
  • Figure 4-13: Regulatory Designations - Benefits
  • Figure 5-1: Multiclonics - Distinctive Characteristics
  • Figure 5-2: Biclonics - Format
  • Figure 5-3: ADAPTIR Bispecific Structure
  • Figure 5-4: ADAPTIR-FLEX
  • Figure 5-5: BEAT Platform - Multispecific Antibodies
  • Figure 5-6: FIT-Ig - Proprietary Bispecific Platform
  • Figure 5-7: BiClone format
  • Figure 5-8: BioAtla CABs - Features
  • Figure 5-9: BioAtla CABs - Benefits
  • Figure 5-10: IMBiologic Bispecific Antibodies - Strategy
  • Figure 5-11: IMBiologic Bispecific Antibodies - Mechanism Of Action
  • Figure 5-12: Novel HBICE
  • Figure 5-13: HBICE - Mechanism Of Action 1
  • Figure 5-14: HBICE - Mechanism Of Action 2
  • Figure 5-15: Phanes Therapeutics - PACbody Platform
  • Figure 5-16: Phanes Therapeutics - SPECpair Platform
  • Figure 5-17: Phanes Therapeutics - ATACCbody
  • Figure 5-18: Numab Therapeutics - Technology
  • Figure 5-19: Grabody I Platform - Mechanism Of Action
  • Figure 5-20: Grabody I Platform - Mechanism Of Action
  • Figure 5-21: 3-Step DuoBody Production Process
  • Figure 5-22: DuoHexaBody Molecules - Schematic
  • Figure 5-23: iTAb - Patented Structure
  • Figure 5-24: iTAb - Mechanism of Action
  • Figure 5-25: Synimmune - Proprietary Bispecific Antibody Format
  • Figure 5-26: BiTE - Structure
  • Figure 5-27: BiTE Molecule
  • Figure 5-28: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
  • Figure 5-29: ALiCE - Characteristics
  • Figure 5-30: ALiCE - Schematic Diagram & Mechanism Of Action
  • Figure 5-31: Abz2 Bispecific Platform
  • Figure 5-32: Abz2 Bispecifics - Benefits
  • Figure 5-33: Neo-X-Prime Bispecific Mechanism
  • Figure 5-34: B-Body Bispecific Antibody - Structre
  • Figure 5-35: xLinkBsAb - Structure
  • Figure 5-36: PrecisionGATE Bispecific Antibody - Structure
  • Figure 6-1: Global - Annual Bispecific Antibody Market (US$ Million), 2020-2025
  • Figure 6-2: Global - Annual Bispecific Antibodies Market By Drugs (US$ Million), 2025
  • Figure 6-3: Global - Bispecific Antibodies Market Shares By Drugs (%), 2025
  • Figure 6-4: Global - Quarterly Bispecific Antibody Market (US$ Million), 2025
  • Figure 6-5: Global - Annual Bispecific Antibody Market By Region (US$ Million), 2025
  • Figure 6-6: Global - Bispecific Antibody Market Shares By Region (%), 2024
  • Figure 6-7: US -Bispecific Antibody Market (US$ Million), 2020-2025
  • Figure 6-8: US - Quarterly Bispecific Antibodies Market (US$ Million), 2025
  • Figure 6-9: ROW -Bispecific Antibody Market Value (US$ Million), 2020-2025
  • Figure 6-10: ROW - Quarterly Bispecific Antibodies Market (US$ Million), 2025
  • Figure 6-11: Blincyto - Total Treatment Cost & Reimbursement Cost
  • Figure 6-12: Blincyto - In Pocket & Out of Pocket Cost of Treatment
  • Figure 6-13: Hemlibra - Total Treatment Cost & Reimbursement Cost
  • Figure 6-14: Hemlibra - In Pocket & Out Of Pocket Cost Of Treatment
  • Figure 6-15: Rybrevant - Maximum Coverage By Medicaid (US$)
  • Figure 6-16: Rybrevant - Maximum Coverage By Private Insurance Coverage (US$)
  • Figure 6-17: Vabysmo - Total Treatment Cost & Reimbursement Cost
  • Figure 6-18: Vabysmo - In Pocket & Out Of Pocket Cost Of Treatment
  • Figure 6-19: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2026 - 2031
  • Figure 7-1: US - Bispecific Antibodies Approval
  • Figure 8-1: Blincyto - Approval Year By Region
  • Figure 8-2: Blincyto - Patent Filing & Expiration Year
  • Figure 8-3: Blincyto - Treatment Regimen Cycles (Weeks)
  • Figure 8-4: Blincyto - Duration Of Treatment Phase & Resting Phase In Induction & Consolidation Cycles For Treatment Of MRD-Positive B-Cell Precursor (Days)
  • Figure 8-5: Blincyto - Recommended Number Of Induction & Consolidation Treatment Cycle For Relapsed B-Cell Precursor ALL
  • Figure 8-6: Blincyto - Duration Of Single Induction, Consolidation, Continued Cycle & Full Treatment For Relapsed B-Cell Precursor ALL (Weeks)
  • Figure 8-7: Global - Blincyto Sales (US$ Million), 2020-2025
  • Figure 8-8: Global - Blincyto Quaterly Sales (US$ Million), 2025
  • Figure 8-9: US - Blincyto Sales (US$ Million), 2020-2025
  • Figure 8-10: US - Blincyto Quaterly Sales (US$ Million), 2025
  • Figure 8-11: ROW - Blincyto Sales (US$ Million), 2020-2025
  • Figure 8-12: ROW - Blincyto Quaterly Sales (US$ Million), 2025
  • Figure 8-13: Hemlibra - Approval Years By Region
  • Figure 8-14: Hemlibra - Cost Per Unit & Supply Of 30 mg/mL Subcutaneous Injection By Volume (US$), March'2026
  • Figure 8-15: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection Of Different Volumes (US$), March'2026
  • Figure 8-16: Hemlibra - Recommended Loading & Maintenance Dose For Treatment Of Hemophilia (mg/kg/Week)
  • Figure 8-17: Global - Hemlibra Sales (US$ Million), 2020-2025
  • Figure 8-18: Global - Hemlibra Quaterly Sales (US$ Million), 2025
  • Figure 8-19: Global - US v/s ROW Sales (US$ Million), 2025
  • Figure 8-20: Global - Hemlibra Sales By Region (US$ Million), 2025
  • Figure 8-21: Global - Hemlibra Sales By Region (%), 2025
  • Figure 8-22: US - Hemlibra Sales (US$ Million), 2020-2025
  • Figure 8-23: US - Hemlibra Quaterly Sales (US$ Million), 2025
  • Figure 8-24: Europe - Hemlibra Sales (US$ Million), 2020-2025
  • Figure 8-25: Europe - Hemlibra Quaterly Sales (US$ Million), 2025
  • Figure 8-26: Japan - Hemlibra Sales (US$ Million), 2020-2025
  • Figure 8-27: Japan - Hemlibra Quaterly Sales (US$ Million), 2025
  • Figure 8-28: ROW - Hemlibra Sales (US$ Million), 2020-2025
  • Figure 8-29: ROW - Hemlibra Quaterly Sales (US$ Million), 2025
  • Figure 8-30: Rybrevant - Patent Filing & Expiration Year
  • Figure 8-31: Rybrevant - Price Per Unit & Supply Of Intravenous Solution (US$), March'2026
  • Figure 8-32: Rybrevant - Recommended Dose Per Cycle By Body Weight (mg)
  • Figure 8-33: Rybrevant - Dose Reduction In Patients With Weight Less Than 80 kg (mg)
  • Figure 8-34: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
  • Figure 8-35: Global - Rybrevant Sales (US$ Million), 2024-2025
  • Figure 8-36: Global - Rybrevant Quaterly Sales (US$ Million), 2025
  • Figure 8-37: US - Rybrevant Sales ((US$ Million), 2024-2025
  • Figure 8-38: US - Rybrevant Quaterly Sales (US$ Million), 2025
  • Figure 8-39: ROW - Rybrevant Sales (US$ Million), 2024-2025
  • Figure 8-40: ROW - Rybrevant Quaterly Sales (US$ Million), 2025
  • Figure 8-41: Vabysmo - Approval Year By Region
  • Figure 8-42: Rybrevant - Patent Filing & Expiration Year
  • Figure 8-43: Vabysmo - Price Per Unit & Supply Of Intravitreal Solution (US$), March'2026
  • Figure 8-44: Global - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 8-45: Global - Vabysmo Quaterly Sales (US$ Million), 2025
  • Figure 8-46: Global - US v/s ROW Sales (US$ Million), 2025
  • Figure 8-47: Global - Vabysmo Sales By Region (US$ Million), 2025
  • Figure 8-48: Global - Vabysmo Sales By Region (%), 2025
  • Figure 8-49: US - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 8-50: US - Vabysmo Quaterly Sales (US$ Million), 2025
  • Figure 8-51: Europe - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 8-52: Europe - Vabysmo Quaterly Sales (US$ Million), 2025
  • Figure 8-53: Japan - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 8-54: Japan - Vabysmo Quaterly Sales (US$ Million), 2025
  • Figure 8-55: ROW - Vabysmo Sales (US$ Million), 2022-2025
  • Figure 8-56: ROW - Vabysmo Quaterly Sales (US$ Million), 2025
  • Figure 8-57: Lunsumio - Approval Years By Region
  • Figure 8-58: US - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2026
  • Figure 8-59: EU - Price Per Unit & Supply of Lunsumio Intravenous Solution (US$), March'2026
  • Figure 8-60: Global - Lunsumio Sales (US$ Million), 2022-2025
  • Figure 8-61: Global - Lunsumio Quaterly Sales (US$ Million), 2025
  • Figure 8-62: Global - US v/s ROW Sales (US$ Million), 2025
  • Figure 8-63: Global - Lunsumio Sales By Region (US$ Million), 2025
  • Figure 8-64: Global - Lunsumio Sales By Region (%), 2025
  • Figure 8-65: US - Lunsumio Sales (US$ Million), 2022-2025
  • Figure 8-66: US - Lunsumio Quaterly Sales (US$ Million), 2025
  • Figure 8-67: Europe - Lunsumio Sales (US$ Million), 2022-2025
  • Figure 8-68: Europe - Lunsumio Quaterly Sales (US$ Million), 2025
  • Figure 8-69: Japan - Lunsumio Sales (US$ Million), 2022-2025
  • Figure 8-70: Japan - Lunsumio Quaterly Sales (US$ Million), 2025
  • Figure 8-71: ROW - Lunsumio Sales (US$ Million), 2022-2025
  • Figure 8-72: ROW - Lunsumio Quaterly Sales (US$ Million), 2025
  • Figure 8-73: China - Kaitani Sales (US$ Million), 2022-2023
  • Figure 8-74: Tecvayli - Approval Years by Region
  • Figure 8-75: Tecvayli - Patent Acceptance & Expiration Year
  • Figure 8-76: US - Cost Per Unit & Supply Of Tecvayli Subcutaneous Solution (US$), March'2026
  • Figure 8-77: EU - Cost of Supply Of Tecvayli Subcutaneous Solution (US$), March'2026
  • Figure 8-78: Global - Tecvayli Sales (US$ Million), 2022-2025
  • Figure 8-79: Tecvayli - US v/s ROW Sales (US$ Million), 2025
  • Figure 8-80: Tecvayli - US v/s ROW Sales (%), 2025
  • Figure 8-81: Global - Tecvayli Quaterly Sales (US$ Million), 2025
  • Figure 8-82: US - Tecvayli Sales (US$ Million), 2022-2025
  • Figure 8-83: US - Tecvayli Quaterly Sales (US$ Million), 2025
  • Figure 8-84: ROW - Tecvayli Sales (US$ Million), 2022-2025
  • Figure 8-85: ROW - Tecvayli Quaterly Sales (US$ Million), 2025
  • Figure 8-86: Columvi - Approval Year By Region
  • Figure 8-87: US - Price Per Unit & Supply Of Columvi Intravenous Solution (US$), March'2026
  • Figure 8-88: EU - Price Of Supply Of Columvi Intravenous Solution (US$), March'2026
  • Figure 8-89: Global - Columvi Sales (US$ Million), 2023-2025
  • Figure 8-90: Global - Columvi Quaterly Sales (US$ Million), 2025
  • Figure 8-91: Global - US v/s ROW Sales (US$ Million), 2025
  • Figure 8-92: Global - Columvi Sales By Region (US$ Million), 2025
  • Figure 8-93: Global - Columvi Sales By Region (%), 2025
  • Figure 8-94: US - Columvi Sales (US$ Million), 2023-2025
  • Figure 8-95: US - Columvi Quaterly Sales (US$ Million), 2025
  • Figure 8-96: Europe - Columvi Sales (US$ Million), 2023-2025
  • Figure 8-97: Europe - Columvi Quaterly Sales (US$ Million), 2025
  • Figure 8-98: ROW - Columvi Sales (US$ Million), 2023-2025
  • Figure 8-99: ROW - Columvi Quaterly Sales (US$ Million), 2025
  • Figure 8-100: Epkinly - Approval Year By Region
  • Figure 8-101: US - Cost Per Unit & Supply Of Epkinly Subcutaneous Solution (US$), March'2026
  • Figure 8-102: EU - Cost Of Supply Of Epkinly Subcutaneous Solution (US$), March'2026
  • Figure 8-103: Global - Epkinly Sales (US$ Million), 2023-2025
  • Figure 8-104: Global - Epkinly Sales Reported By Genmab (US$ Million), 2023-2025
  • Figure 8-105: Global - Epkinly Sales Reported By AbbVie (US$ Million), 2023-2025
  • Figure 8-106: Global - Epkinly Quaterly Sales (US$ Million), 2025
  • Figure 8-107: Talvey - Approval Year By Region
  • Figure 8-108: Talquetamab - FDA & EMA Designation Year
  • Figure 8-109: Talvey - Patent Acceptance & Expiration Year
  • Figure 8-110: US - Price Per Unit & Supply Of Talvey Intravenous Solution (US$), March'2026
  • Figure 8-111: EU - Price Per Supply Of Talvey Intravenous Solution (US$), March'2026
  • Figure 8-112: Global - Talvey Sales (US$ Million), 2024-2025
  • Figure 8-113: Global - Talvey Quaterly Sales (US$ Million), 2025
  • Figure 8-114: US - Talvey Sales ((US$ Million), 2024-2025
  • Figure 8-115: US - Talvey Quaterly Sales (US$ Million), 2025
  • Figure 8-116: ROW - Talvey Sales (US$ Million), 2024-2025
  • Figure 8-117: ROW - Talvey Quaterly Sales (US$ Million), 2025
  • Figure 8-118: Elrexfio - Approval Year by Region
  • Figure 8-119: Elranatamab - FDA & EMA Designation Year
  • Figure 8-120: US - Price Per Unit & Supply Of Elrexfio Subcutaneous Solution (US$), March'2026
  • Figure 8-121: Global - Elrexfio Sales (US$ Million), 2023-2025
  • Figure 8-122: Global - Elrexfio Quaterly Sales (US$ Million), 2025
  • Figure 8-123: US - Elrexfio Sales (US$ Million), 2023-2025
  • Figure 8-124: Global - Elrexfio Quaterly Sales (US$ Million), 2025
  • Figure 8-125: ROW - Elrexfio Sales (US$ Million), 2023-2025
  • Figure 8-126: Global - Elrexfio Quaterly Sales (US$ Million), 2025
  • Figure 8-127: Imdelltra - Approval Year By Region
  • Figure 8-128: US - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2026
  • Figure 8-129: EU - Price Of Supply Of Imdelltra Intravenous Powder (US$), March'2026
  • Figure 8-130: Global - Imdelltra Sales (US$ Million), 2024-2025
  • Figure 8-131: Global - Imdelltra Quaterly Sales (US$ Million), 2025
  • Figure 8-132: US - Imdelltra Sales ((US$ Million), 2024-2025
  • Figure 8-133: US - Imdelltra Quaterly Sales (US$ Million), 2025
  • Figure 8-134: ROW - Imdelltra Sales (US$ Million), 2024-2025
  • Figure 8-135: ROW - Imdelltra Quaterly Sales (US$ Million), 2025
  • Figure 8-136: EU - Price Of Supply Of Ordspono Intravenous Powder (US$), March'2026
  • Figure 8-137: US & EU - Price Per Unit & Supply Of Ziihera (US$), March'2026
  • Figure 8-138: Global - Ziihera Sales (US$ Million), 2024-2025
  • Figure 8-139: Global - Ziihera Quaterly Sales (US$ Million), 2025
  • Figure 8-140: Zenocutuzumab - Active Patents
  • Figure 8-141: US - Price Of Supply Of Bizengri Intravenous Solution (US$), March'2026
  • Figure 8-142: US - Price Per Unit & Supply of Lynozyfic Intravenous Solution, March'2026
  • Figure 9-1: Global - Number of Bispecific Antibodies In Clinical Pipeline By Phase, 2026 Till 2031
  • Figure 11-1: MK-1045-002 Phase I/II Study (NCT05579132) - Initiation & Completion Year
  • Figure 11-2: LINKER-MM1 Phase I/II Study (NCT03761108) - Initiation & Completion Year
  • Figure 11-3: LBL-034-CN001 Phase I/II Study (NCT06049290) - Initiation & Completion Year
  • Figure 11-4: LINKER-SMM1 Phase II Study (NCT05955508) - Initiation & Completion Year
  • Figure 11-5: EPCORE FL-1 Phase III Study (NCT05409066) - Initiation & Completion Year
  • Figure 11-6: EPCORE(TM) NHL-2 Phase I/II Study (NCT04663347) - Initiation & Completion Year
  • Figure 11-7: COALITION Phase I/II Study (NCT04914741) - Initiation & Completion Year
  • Figure 11-8: ELM-2 Phase II Study (NCT03888105) - Initiation & Completion Year
  • Figure 11-9: OLYMPIA-1 Phase III Study (NCT06091254) - Initiation & Completion Year
  • Figure 11-10: OLYMPIA-2 Phase III Study (NCT06097364) - Initiation & Completion Year
  • Figure 11-11: OLYMPIA-3 Phase III Study (NCT06091865) - Initiation & Completion Year
  • Figure 11-12: OLYMPIA-4 Phase III Study (NCT06230224) - Initiation & Completion Year
  • Figure 11-13: OLYMPIA-5 Phase III Study (NCT06149286) - Initiation & Completion Year
  • Figure 11-14: HX009-I-01 Phase I Study (NCT05731752) - Initiation & Completion Year
  • Figure 11-15: HX009-II-01 Phase I/II Study (NCT04886271) - Initiation & Completion Year
  • Figure 11-16: DeLLphi-304 Phase III Study (NCT05740566) - Initiation & Completion Year
  • Figure 11-17: HARMONi Phase III Study (NCT06396065) - Initiation & Completion Year
  • Figure 11-18: HARMONi-6 Phase III Study (NCT05840016) - Initiation & Completion Year
  • Figure 11-19: HERIZON-GEA-01 Phase III Study (NCT05152147) - Initiation & Completion Year
  • Figure 11-20: eNRGy Phase II Study (NCT02912949) - Initiation & Completion Year
  • Figure 11-21: AK104-303 Phase III Study (NCT02912949) - Initiation & Completion Year
  • Figure 11-22: AK104-308 Phase II Study (NCT06371157) - Initiation & Completion Year
  • Figure 11-23: TWINPEAK Phase I/II Study (NCT05482893) - Initiation & Completion Year
  • Figure 11-24: SKYBRIDGE Phase I/II Study (NCT05652686) - Initiation & Completion Year
  • Figure 11-25: CIBI389A101 Phase I Study (NCT02912949) - Initiation & Completion Year
  • Figure 11-26: INCA 33890-101 Phase I Study (NCT05836324) - Initiation & Completion Year
  • Figure 11-27: INCA033890-303 Phase III Study (NCT07284849) - Initiation & Completion Year
  • Figure 11-28: COMPANION-002 Phase II/III Study (NCT05506943) - Initiation & Completion Year
  • Figure 11-29: BNT327-02 Phase II Study (NCT06449222) - Initiation & Completion Year
  • Figure 11-30: RNDO-564-001 Phase I Study (NCT07218003) - Initiation & Completion Year
  • Figure 11-31: LBL-033-CN001 Phase I/II Study (NCT05779163) - Initiation & Completion Year
  • Figure 11-32: NAV-240-201 Phase II Study (NCT07384975) - Initiation & Completion Year
  • Figure 11-33: ZL-1503-001 Phase I Study (NCT07235384) - Initiation & Completion Year
  • Figure 11-34: FRONTIER 4 Phase III Study (NCT05685238) - Initiation & Completion Year
  • Figure 11-35: NXTAGE Phase I/II Study (NCT05987449) - Initiation & Completion Year
  • Figure 11-36: HMB-001-CL101 Phase II Study (NCT06211634) - Initiation & Completion Year
  • Figure 11-37: PEAK Phase III Study (NCT06990399) - Initiation & Completion Year
  • Figure 11-38: PINNACLE Phase III Study (NCT06996080) - Initiation & Completion Year
  • Figure 11-39: RV584 Phase I Study (NCT05890963) - Initiation & Completion Year
  • Figure 11-40: 001965-I Phase I Study (NCT06585891) - Initiation & Completion Year

List of Tables

  • Table 3-1: Clinically Approved Bispecific Antibody Combinations
  • Table 3-2: Bispecific Antibody & Chemotherapy Combinations In Clinical Trials
  • Table 3-3: Bispecific Antibody & Targeted Therapy Combinations In Clinical Trials
  • Table 3-4: Bispecific Antibody & Immunotherapy Combinations In Clinical Trials
  • Table 3-5: Bispecific Antibody & Radiotherapy Combinations In Clinical Trials
  • Table 4-1: Approved Bispecific Antibodies
  • Table 4-2: US - Bispecific Antibodies With Regulatory Designations
  • Table 4-3: EU - Bispecific Antibodies With Regulatory Designations
  • Table 4-4: China - Bispecific Antibodies with Regulatory Designations
  • Table 6-1: Epkinly - Billing Unit Application For Doses
  • Table 6-2: Talvey - Coverage Summary
  • Table 6-3: Talvey - Coding Summary
  • Table 6-4: Elrexfio - HCPCS Codes
  • Table 6-5: Elrexfio - HCPCS Modifiers
  • Table 6-6: Imdelltra - Payer Coverage & Reimbursement Details
  • Table 6-7: Ziihera - ICD-10-CM Codes
  • Table 6-8: Ziihera - ICD-10-PCS Codes
  • Table 6-9: LYNOZYFIC - HCPCS code
  • Table 8-1: Blincyto - Active Patents
  • Table 8-2: Blincyto - Recommended Dosage & Schedule For The Treatment of MRD-Positive B-Cell Precursor ALL
  • Table 8-3: Blincyto - Recommended Dosage & Schedule for Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
  • Table 8-4: Blincyto - Recommended Dosage & Schedule For Treatment Of Relapsed Or Refractory B-Cell Precursor ALL
  • Table 8-5: Rybrevant - Premedication
  • Table 8-6: Rybrevant - Dose Reductions For Adverse Reactions
  • Table 8-7: Rybrevant - Recommended Dosage Modifications For Adverse Reactions
  • Table 8-8: Lunsumio - Recommended Treatment Cycles
  • Table 8-9: Lunsumio - Recommended Premedications
  • Table 8-10: Lunsumio - Recommendations For Management Of Cytokine Release Syndrome
  • Table 8-11: Tecvayli - Dosing Schedule
  • Table 8-12: Tecvayli - Recommended Dosage Modifications For Adverse Reactions
  • Table 8-13: Columvi - Dosing Schedule (21-Day Treatment Cycles)
  • Table 8-14: Columvi - Premedications To Be Administered
  • Table 8-15: Columvi - Recommendations For Management Of Cytokine Release Syndrome
  • Table 8-16: Columvi - Recommended Dosage Modification For Neurologic Toxicity (Including ICANS)
  • Table 8-17: Columvi - Recommended Dosage Modifications For Other Adverse Reactions
  • Table 8-18: Epkinly - Dosage Schedule
  • Table 8-19: Epkinly - Recommendations For Management Of Cytokine Release Syndrome
  • Table 8-20: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 8-21: Epkinly - Recommended Dosage Modifications For Other Adverse Reactions
  • Table 8-22: Talvey - Weekly Dosing Schedule
  • Table 8-23: Talvey - Biweekly Dosing Schedule
  • Table 8-24: Talvey - Recommendations For Management of CRS
  • Table 8-25: Talvey - Recommendations For Management Of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
  • Table 8-26: Talvey - Recommendations For Management Of Neurologic Toxicity (excluding ICANS)
  • Table 8-27: Talvey - Recommended Dosage Modifications For Other Adverse Reactions
  • Table 8-28: Elrexfio - Dosing Schedule
  • Table 8-29: Elrexfio - Recommendations For Management Of CRS
  • Table 8-30: Elrexfio - Recommended Dosage Modifications For Other Adverse Reactions
  • Table 8-31: Ordspono - Recommended Dose
  • Table 8-32: Ordspono - Premedications & Post-Medications For Patients With r/r FL Or r/r DLBCL
  • Table 8-33: Ordspono - Recommendations For Management Of Cytokine Release Syndrome
  • Table 8-34: Ziihera - Dosage Modifications For Adverse Reactions
  • Table 8-35: Bizengri - Premedications Prior To Infusions
  • Table 8-36: Bizengri - Premedications Prior to Infusions
  • Table 8-37: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions
  • Table 8-38: Korjuny - Dosing Schedule
  • Table 8-39: Lynozyfic - Dosing Schedule
  • Table 8-40: Lynozyfic - Recommendations for Restarting Therapy After a Dose Delay